Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.16 +1.55 (+3.00%)
Streaming Delayed Price Updated: 1:39 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React ↗
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi. 
Via Stocktwits
Topics Government
News headline image
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
From Genentech
Via Business Wire
News headline image
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
From Genentech
Via Business Wire
News headline image
The Smartest Vanguard ETF to Buy With $500 Right Now ↗
Via The Motley Fool
Topics ETFs
News headline image
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
News headline image
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
News headline image
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
News headline image
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases ↗
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront. 
Via Benzinga
News headline image
Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗
Via The Motley Fool
Topics Government
News headline image
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% ↗
Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime 
Via Benzinga
News headline image
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
From Genentech
Via Business Wire
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Roche and Genentech Announce New North Carolina Manufacturing Facility
From Genentech
Via Business Wire
News headline image
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription... 
Via Benzinga
Topics Government
News headline image
Down Nearly 20%: Should You Buy the Dip on Eli Lilly? ↗
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low ↗
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment. 
Via Investor's Business Daily
Topics Death
News headline image
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
News headline image
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
News headline image
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
From Genentech
Via Business Wire
News headline image
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed ↗
Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated. 
Via Investor's Business Daily
Topics Earnings Government
News headline image
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs ↗
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
News headline image
Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom ↗
Roche plans $50B investment in U.S. for manufacturing & research, as potential drug tariffs loom. Move to create 12,000 jobs & increase exports 
Via Benzinga
Topics World Trade
News headline image
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
News headline image
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
News headline image
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today ↗
Might the tariff risk for pharmaceutical stocks be less than you think? 
Via The Motley Fool
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.